United Therapeutics Corp (UTHR)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing innovative therapies for patients with chronic and life-threatening conditions. Founded in 1996, the company specializes in treatments for pulmonary arterial hypertension and related conditions, leveraging biotechnological advances to improve patient outcomes.
Company News
Despite ongoing global tensions, the stock market showed resilience during the holiday season, with the S&P 500 and Nasdaq rising. Three high-growth stocks - PDD Holdings, Alphabet, and United Therapeutics - demonstrated strong performance and potential for continued gains through year-end.
MannKind reported Q2 2025 revenue of $76.5 million, slightly missing analyst estimates. The company saw growth in Afrezza inhaled insulin sales and Tyvaso DPI royalties, while increasing R&D and marketing expenses.
Rosen Law Firm is pursuing a securities class action lawsuit against 3D Systems Corporation, alleging the company made false or misleading statements about its business performance and partnership impacts during the period of August 13, 2024 to May 12, 2025.
Several large-cap stocks, including AppLovin, Chewy, and Carvana, were among the top losers last week. The declines were attributed to factors such as weak earnings guidance, lower-than-expected sales outlook, and bearish options activity.
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeutics.